Breo Ellipta Sales Below Estimates, Says Leerink Swann (THRX) (GSK)
Tweet
Share
E-mailGet Alerts THRX Hot Sheet
Price: $4.06 --0%
Rating Summary:
6 Buy, 5 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 6 | New: 33
Rating Summary:
6 Buy, 5 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 6 | New: 33
Join SI Premium – FREE
GlaxoSmithKline plc (NYSE: GSK) and Theravance's (NASDAQ: THRX) Breo Ellipta sales are well below estimates, said Leerink Swann, cited IMS data. Scripts were roughly flat at 1,634 last week. Analyst Howard Liang said "significant acceleration" is needed to meet estimates.
Leerink Swann has a Outperform rating on Theravance Inc. with a price target of $50.00
For an analyst ratings summary and ratings history on Theravance Inc. click here. For more ratings news on Theravance Inc. click here.
Shares of Theravance Inc. closed at $33.94 yesterday.
Leerink Swann has a Outperform rating on Theravance Inc. with a price target of $50.00
For an analyst ratings summary and ratings history on Theravance Inc. click here. For more ratings news on Theravance Inc. click here.
Shares of Theravance Inc. closed at $33.94 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kepler Cheuvreux Upgrades Entain PLC (ENT:LN) (GMVHF) to Buy
- Protagonist Therapeutics (PTGX) PT Raised to $190 at BMO Capital
- BofA Securities Resumes Element Solutions (ESI) at Buy
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
